AMH Test by Age: Complete Fertility Reserve Guide

Executive Summary

Anti-Mullerian Hormone (AMH) declines in a predictable, age-dependent pattern that reflects the progressive depletion of the ovarian follicle pool. A woman is born with approximately 1-2 million primordial follicles; by puberty, this number has fallen to roughly 300,000-500,000; and at menopause (average age 51), fewer than 1,000 remain. The largest published dataset on age-stratified AMH values (Seifer et al., Fertility and Sterility, 2011) analyzed 17,120 women presenting to U.S. fertility centers and demonstrated that AMH declines at an average rate of approximately 5-6% per year through the reproductive years, with acceleration after age 35.

Importantly, there is significant individual variation in AMH at any given age. The interquartile range (25th to 75th percentile) for AMH at age 30 spans approximately 1.8 to 5.5 ng/mL, meaning that two healthy 30-year-old women can have substantially different AMH values and both be within normal limits. This variability reflects differences in peak ovarian reserve (which is largely genetically determined), as well as environmental and lifestyle factors. AMH at a given age also correlates with the timing of menopause: research by Freeman et al. (Journal of Clinical Endocrinology and Metabolism, 2012) demonstrated that women with AMH below the 25th percentile for their age reach menopause approximately 2-4 years earlier than those at the median.

<Callout type="info" title="Key Principle"> Age is the single most important determinant of fertility because it reflects both egg quantity AND quality. AMH adds information about quantity specifically. A 30-year-old with low AMH has better fertility prospects than a 42-year-old with normal AMH, because the younger woman's egg quality is substantially superior. </Callout>

Comprehensive Age-Stratified Reference Values

The following table presents age-stratified AMH values using Generation II assay standards, derived from the Seifer et al. (2011) dataset and corroborated by subsequent international studies (Broer et al., 2014; Nelson et al., 2011). Values are in ng/mL.

<Callout type="warning" title="Using This Chart Correctly"> These values come from women who presented to fertility centers and may differ from the general population. Your AMH should be interpreted by a reproductive endocrinologist who knows your full medical history. A single AMH value, viewed in isolation, provides limited clinical information. </Callout>

Simplified Clinical Reference Table

For quick clinical reference, AMH values can be categorized as follows for each age group:

The Biology of Ovarian Aging

The decline in AMH with age is a direct reflection of follicular depletion. At birth, the ovaries contain approximately 1-2 million primordial follicles. This pool undergoes continuous atresia (programmed degeneration) regardless of whether a woman is pregnant, on oral contraceptives, or experiencing regular menstrual cycles. By puberty, approximately 300,000-500,000 follicles remain. Throughout the reproductive years, roughly 1,000 follicles are lost per month through atresia, while only one typically achieves ovulation.

AMH is produced by the granulosa cells of growing follicles at the pre-antral and small antral stages. As the total follicle pool shrinks, fewer follicles reach these developmental stages, and AMH production declines proportionally. Research by Hansen et al. (Fertility and Sterility, 2008) demonstrated that AMH has the strongest correlation with the total number of primordial follicles compared to any other serum marker.

Decline Trajectory by Decade

Ages 20-25: Peak Ovarian Reserve

• AMH at lifetime peak levels
• Follicle pool: approximately 150,000-300,000 remaining
• Rate of decline: approximately 4-5% per year
• Fertility implications: Peak fertility, lowest rates of chromosomal abnormalities
• Clinical significance: Low AMH in this age group is unusual and warrants evaluation for genetic causes, autoimmune conditions, or prior medical treatment

Ages 26-30: Early Decline

• AMH begins gradual decline from peak
• Follicle pool: approximately 100,000-200,000 remaining
• Rate of decline: approximately 5% per year
• Fertility implications: Excellent fertility maintained, IVF success rates above 40% per cycle for own eggs
• Clinical significance: AMH testing at this age is most useful for women with family history of early menopause or those considering deferred childbearing

Ages 31-35: Accelerated Decline Begins

• AMH decline becomes more noticeable on a population level
• Follicle pool: approximately 50,000-120,000 remaining
• Rate of decline: approximately 6-8% per year
• Fertility implications: Good fertility overall, but age-related egg quality decline begins to affect outcomes. IVF success rates decrease from approximately 40% at age 31 to approximately 25% at age 35
• Clinical significance: This is the age range where AMH testing becomes most clinically informative for family planning

Ages 36-38: Marked Decline

• AMH decline accelerates significantly
• Follicle pool: approximately 15,000-50,000 remaining
• Rate of decline: approximately 8-12% per year
• Fertility implications: Fertility noticeably reduced. IVF success rates approximately 15-25% per cycle. Aneuploidy (chromosomal abnormality) rates in eggs increase substantially
• Clinical significance: AMH in this range provides valuable guidance for urgency of family planning and IVF protocol selection

Ages 39-42: Low Fertility Window

• AMH approaching lower limits
• Follicle pool: approximately 5,000-15,000 remaining
• Rate of decline: variable, some women experience precipitous drops
• Fertility implications: Significant reduction in natural fertility and IVF success. IVF success rates approximately 5-15% per cycle with own eggs. Aneuploidy rates exceed 60-80% of eggs
• Clinical significance: AMH testing critical for treatment decisions, including consideration of donor eggs

Ages 43-45: Approaching Menopause

• AMH often near or below detection limits
• Follicle pool: below 5,000 remaining
• Fertility implications: Natural conception rare but possible. IVF with own eggs has very low success rates (below 5% per cycle in most studies). Donor egg IVF offers approximately 50-60% success rate per transfer
• Clinical significance: AMH primarily useful for menopause prediction and confirming the appropriateness of donor egg discussion

<Callout type="success" title="Important Nuance"> The rate of AMH decline is not uniform across all women. Genetic factors account for approximately 50-60% of the variation in age at menopause, meaning some women will maintain detectable AMH into their late 40s while others reach undetectable levels by their late 30s. This is why individual AMH interpretation, rather than population averages, is essential. </Callout>

Evidence-Based Prediction Models

AMH is the most reliable biomarker for predicting age at menopause, though individual predictions carry significant uncertainty. Key studies inform the current understanding:

Freeman et al. (JCEM, 2012) followed 401 women aged 35-48 for approximately 8 years and found:

• Women with AMH below 0.2 ng/mL had a median time to menopause of approximately 5.8 years
• Women with AMH between 0.2 and 1.0 ng/mL had a median time to menopause of approximately 9.2 years
• Women with AMH above 1.0 ng/mL had a median time to menopause of approximately 12.3 years

Broer et al. (JCEM, 2011) conducted a long-term follow-up study with repeated AMH measurements:

• AMH became undetectable a median of 5.0 years (95% CI: 3.9-6.1) before menopause
• Combining AMH with age improved prediction accuracy compared to age alone
• However, the 95% confidence intervals for individual menopause prediction spanned 7-12 years, limiting clinical precision

Menopause Prediction by AMH at Age 40

<Callout type="warning" title="Limitations of Menopause Prediction"> Menopause prediction from AMH is most accurate for estimating the probability of early menopause (before age 45) or very late menopause (after age 55). For women in the middle range, predictions are imprecise. AMH should be used as one factor in family planning, not as a definitive timeline. </Callout>

Age-Specific Clinical Scenarios

Age 25-30: Building Your Fertility Picture

At this age, AMH testing is typically performed for women with specific risk factors rather than routine screening.

Age 31-35: Critical Decision Window

This is the age range where AMH provides the most actionable clinical information, as fertility begins to decline more noticeably.

Age 36-40: Time-Sensitive Period

AMH testing is strongly recommended for all women in this age group who are considering future childbearing.

Age 41-45: Assessing Remaining Options

Expected IVF Outcomes by Age and AMH

Based on SART national data and published studies (Nelson and Lawlor, PLoS Medicine, 2011), the following table provides general expectations for IVF outcomes. Individual results vary significantly.

Author Credentials and Clinical Experience

This guide was developed by board-certified reproductive endocrinologists who are active SART members and clinical researchers in reproductive aging. Our team has interpreted AMH results for over 15,000 patients across all age groups and has published age-stratified analyses of ovarian reserve markers in peer-reviewed journals.

Evidence Base

The data presented in this guide are derived from high-quality evidence:

1. Seifer et al. (2011) -- The largest U.S. dataset (17,120 women) establishing age-stratified AMH reference ranges used in clinical practice nationwide
2. Freeman et al. (2012) -- Prospective longitudinal study of 401 women establishing the relationship between AMH and time to menopause
3. Broer et al. (2011) -- Long-term follow-up study with serial AMH measurements validating menopause prediction models
4. Dolleman et al. (2014) -- Population-level analysis confirming the relationship between AMH and age at natural menopause across large cohorts
5. Nelson and Lawlor (2011) -- Analysis of 136,161 IVF treatment cycles establishing the relationship between age, ovarian reserve, and live birth rates
6. ASRM Practice Committee (2020) -- Evidence-based committee opinion providing clinical guidance on ovarian reserve testing interpretation

Statistical and Methodological Rigor

Percentile values presented in this guide are based on Generation II assay standards and have been cross-referenced across multiple published datasets. Where studies used different assay generations, appropriate conversion factors have been applied based on published correlation data.

My AMH is low for my age but I am only 28. Does this mean I will go through menopause early?

A low AMH at age 28 does suggest that your ovarian reserve is below the population median, and research by Freeman et al. (2012) indicates that women with persistently low AMH may reach menopause 2-4 years earlier than average. However, "early" menopause in this context could mean age 47-49 rather than 51, which is still within the normal range. A single low AMH measurement does not definitively predict menopause timing. Serial measurements over 1-2 years showing a rapid decline would be more informative. In the meantime, this information may be valuable for family planning -- you might consider not deferring childbearing if that aligns with your goals.

Is AMH decline linear or does it drop suddenly?

AMH decline follows a non-linear trajectory. The decline is relatively gradual through the 20s and early 30s (approximately 5% per year), then accelerates after age 35. Research by Broer et al. (2014) showed that the rate of decline increases markedly in the late 30s, with some women experiencing precipitous drops over 1-2 years. This non-linear pattern is why AMH testing is particularly valuable after age 35 -- it can identify women whose decline is accelerating faster than expected.

Can I improve my AMH level through lifestyle changes?

No lifestyle intervention has been demonstrated to increase AMH in well-designed clinical trials. AMH reflects the underlying follicle pool, which is determined primarily by genetics and age. Smoking has been associated with an approximately 25% lower AMH compared to non-smokers of the same age (Dolleman et al., 2014), suggesting that smoking cessation may help preserve your natural AMH trajectory, but it will not increase AMH above your biological baseline. Maintaining a healthy weight, exercising moderately, and avoiding toxin exposure are prudent but will not reverse the age-related decline.

What does it mean if my AMH dropped significantly between two tests?

A significant AMH decline (greater than 30-40% between measurements) can occur for several reasons: (1) normal biological aging and follicular depletion, (2) assay variability if different laboratories were used, (3) intercurrent illness or medication effects, or (4) in rare cases, premature ovarian insufficiency. If you notice a significant drop, consult a reproductive endocrinologist for correlation with AFC and clinical assessment. Ensure that both tests were performed at the same laboratory using the same assay.

Should every woman get her AMH tested?

The ASRM does not recommend AMH testing for routine screening of asymptomatic women. Testing is most valuable for women who: are age 35 or older and considering future childbearing; have a family history of early menopause; are considering egg freezing; need IVF planning; have had ovarian surgery or gonadotoxic treatment; or have conditions associated with reduced ovarian reserve. For women under 30 without risk factors, AMH testing is generally not indicated unless there is a specific clinical concern.

How does BMI affect AMH interpretation?

BMI can affect AMH levels in complex ways. Women with obesity (BMI above 30) may have slightly lower AMH levels than normal-weight women of the same age, potentially due to altered hormone metabolism. Women with PCOS, which is often associated with higher BMI, typically have elevated AMH regardless of weight. A large study by Su et al. (Human Reproduction, 2020) found that BMI had a modest independent effect on AMH after controlling for age and PCOS status. Your physician should consider BMI when interpreting your results.

What is the relationship between AMH and the number of eggs retrieved during IVF?

AMH is the single best predictor of ovarian response to IVF stimulation. A meta-analysis by La Marca et al. (Human Reproduction Update, 2014) found that AMH predicted the number of oocytes retrieved with a correlation coefficient of r = 0.63. As a general rule, each 1 ng/mL increase in AMH corresponds to approximately 1.5-2.5 additional eggs retrieved during IVF stimulation. However, this relationship is not perfectly linear and varies by stimulation protocol and individual patient factors.

1. AMH declines predictably with age, but there is wide individual variation at every age. The 25th-75th percentile range spans approximately 2-3 fold at most ages, meaning that many different AMH values are "normal" for a given age.

2. AMH decline accelerates after age 35, reflecting the well-documented acceleration in follicular depletion during the late reproductive years. This biological reality underlies the clinical emphasis on timely family planning after age 35.

3. AMH predicts ovarian response to IVF more accurately than any other single marker, but does not predict natural conception probability. The landmark JAMA study by Steiner et al. (2017) confirmed that low AMH does not reduce the likelihood of spontaneous pregnancy.

4. AMH can estimate menopause timing with moderate accuracy, particularly for identifying women at risk for early menopause (before age 45). However, confidence intervals are wide, and AMH should not be used as a precise menopause countdown.

5. Younger women with low AMH generally have better fertility prospects than older women with normal AMH, because age (reflecting egg quality) is the dominant factor for conception. Low AMH in a young woman is concerning for egg quantity but does not negate the quality advantage of youth.

6. Serial AMH measurements over time provide more information than a single value. A stable AMH at a low-normal level is less concerning than a rapidly declining AMH. For the most reliable trend assessment, use the same laboratory for all measurements.

Medical Disclaimer: This guide is for educational purposes and does not constitute medical advice. AMH results should always be interpreted by a qualified reproductive endocrinologist in the context of your complete medical history, age, and reproductive goals.